Business context and reporting period
Medpace Holdings, Inc. is a global clinical research organization providing outsourced Phase I–IV drug and medical-device development services. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2021; comparisons are with the same 2020 periods. Amounts below are in millions of dollars unless noted.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $278.3 | $205.0 | $538.3 | $435.9 |
| Operating income | $42.4 | $30.1 | $90.0 | $65.6 |
| Operating margin | 15.3% | 14.7% | 16.7% | 15.1% |
| Net income | $39.9 | $24.1 | $83.2 | $53.1 |
| Net margin | 14.4% | 11.8% | 15.5% | 12.2% |
| Diluted EPS | $1.06 | $0.64 | $2.20 | $1.40 |
- Cash flow: First-half operating cash flow was $120.1, versus $93.4 a year earlier. Capital expenditures were $12.5; approximate operating cash flow less capital expenditures was $107.6. Cash increased by $61.2 to $339.0.
- Liquidity and debt: Current assets were $550.1 and current liabilities $472.6 at June 30, 2021, implying working capital of $77.5. The company had no borrowings and $49.8 available under its $50 million revolving facility; $0.2 of letters of credit was outstanding. Operating lease liabilities totaled $128.0.
- Contract indicators: Backlog was $1,742.6, up 29.8% year over year; $915–$935 was expected to convert to revenue over the next 12 months. Net new awards were $387.6 for Q2 and $743.7 for the first half. Separately, remaining performance obligations for active projects were approximately $1.9 billion.
Changes versus prior comparable periods
- Q2 revenue rose 35.8% and first-half revenue rose 23.5%. Management attributed growth chiefly to Oncology, CNS, Metabolic and other therapeutic areas in Q2, and Oncology, CNS, AVAI and other areas for the first half.
- Q2 operating income increased 40.9%; first-half operating income increased 37.2%. Direct costs rose 37.3% in Q2 and 22.6% in the first half, reflecting higher reimbursable out-of-pocket expenses and personnel costs supporting increased activity.
- The effective tax rate declined to 6.4% in Q2 and 8.7% for the first half, from 20.6% in both prior-year periods. The filing cites excess share-based compensation tax benefits and Foreign Derived Intangible Income benefits.
- First-half operating cash flow increased, supported in part by higher advanced billings and accrued expenses. The company repurchased $55.9 of stock in the first half; Q2 repurchases were $56.1. The repurchase authorization was increased to $300 million, with $196.4 remaining at quarter-end.
Outlook, risks and unusual items
- No specific revenue or earnings guidance is provided. Management said it expected $915–$935 of backlog to convert within the next 12 months, while cautioning that backlog and awards are not necessarily reliable predictors of future revenue.
- COVID-19 continued to affect clinical-site access, patient enrollment and trial start-up. Management described expected effects as temporary but warned that disruptions could delay or cancel studies and that smaller clients may have difficulty securing funding; the eventual financial impact could not be reasonably estimated.
- Most customer contracts can be terminated, generally with 30 days’ notice. Cancellations, changes in project scope, study timing and foreign exchange can affect revenue and backlog.
- Related-party matters merit attention: the company reported revenue from clients with executive or employee board and investment connections, and leases certain Cincinnati properties from entities owned by the CEO and family members. The filing also disclosed CEO-connected private aviation services. Legal proceedings and purchase commitments were described as immaterial or ordinary-course matters; project-supply minimum purchase commitments totaled $12.3.
- The lower tax rate materially benefited reported earnings. Share repurchases were a significant use of cash. COVID-related uncertainty and long-term lease commitments are additional items to monitor.
Investor verification points
- Check subsequent filings for backlog conversion, new awards, cancellations and the portion of backlog expected within 12 months.
- Assess whether elevated revenue growth and margins persist as personnel and reimbursable costs scale.
- Review the sustainability of the unusually low effective tax rate and its effect on earnings comparisons.
- Monitor operating cash flow and working-capital movements, particularly advanced billings and prepaid expenses.
- Review the pace and pricing of repurchases, remaining authorization, and related-party revenue and lease disclosures.